Press Releases

Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology

SOUTH SAN FRANCISCO, Calif., June 29, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that the company and its ProNeura™ long-term, continuous drug delivery technology have been featured in Fortune in an article titled "The Buzzy New Technology That Could Make Pills Obsolete."

The article discusses how "pharmaceutical implants, matchstick-size devices that deliver drugs to patients over a period of weeks or months, are coming into their own." Specifically, the article highlights Titan's FDA-approved Probuphine® (buprenorphine) implant product, which treats opioid addiction by providing continuous doses of buprenorphine for up to six months, and that is being commercialized in the United States by its partner, Braeburn Pharmaceuticals, as well as Titan's development of its ProNeura implantable technology for Parkinson's disease.

In addition to the article, Fortune posted an in-depth video interview with Dr. Kate Beebe, Titan's executive vice president and chief development officer. The article and video appear online here and a version of the article is expected to appear in the July 1 print issue of Fortune.

About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted commercial rights in the U.S. and Canada for Probuphine to Braeburn Pharmaceuticals. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


Titan Pharmaceuticals, Inc.:
Sunil Bhonsle, President
(650) 244-4990

Stephen Kilmer
(650) 989-2215

Susan Thomas
(650) 989-2216


To view the original version on PR Newswire, visit:

SOURCE Titan Pharmaceuticals, Inc.